Vir Biotechnology to Participate in the Barclays Global Healthcare Conference
08 mars 2023 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head...
Vir Biotechnology to Participate in the Cowen 43rd Annual Health Care Conference
28 févr. 2023 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Bolyn Hubby, Ph.D., Executive Vice President and Chief Corporate Affairs Officer, will...
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
23 févr. 2023 16h05 HE
|
Vir Biotechnology, Inc.
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact – – $1.5 billion of...
Vir Biotechnology Announces Positive Final Draft Guidance on Sotrovimab from the UK’s National Institute for Health and Care Excellence (NICE)
22 févr. 2023 08h30 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the UK’s National Institute for Health and Care Excellence (NICE) provided positive final...
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
16 févr. 2023 16h05 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter...
Vir Biotechnology Appoints Sung Lee as Chief Financial Officer
16 févr. 2023 08h30 HE
|
Vir Biotechnology, Inc.
– Experienced biotech executive brings more than 20 years of financial leadership to Vir – – Howard Horn departing to pursue next chapter; will remain in an advisory role through a brief transition...
Vir Biotechnology Announces Amended Collaboration Agreement with GSK
13 févr. 2023 16h45 HE
|
Vir Biotechnology, Inc.
– Vir to continue advancing next-generation COVID-19 solutions independently or with other partners – – The Companies will continue working together to ensure ongoing access to sotrovimab for...
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
25 janv. 2023 08h29 HE
|
Vir Biotechnology, Inc.
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue providing strategic counsel...
Vir Biotechnology to Highlight Anticipated 2023 Catalysts and Long-Term Growth Strategy at 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 16h05 HE
|
Vir Biotechnology, Inc.
– Critical Phase 2 readouts anticipated in 2023 for three advanced programs – hepatitis B, hepatitis D and influenza – – Strong balance sheet expected to fund Vir’s robust portfolio through major...
Vir Biotechnology Achieves Target Enrollment for Groundbreaking Phase 2 PENINSULA Trial Evaluating VIR-2482 for Prevention of Seasonal Influenza A
21 déc. 2022 08h00 HE
|
Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it has achieved the target enrollment of approximately 3,000 participants in the groundbreaking...